Scholarlink

Aim <p>Overweight and obesity are global public health challenges characterized by chronic low-grade inflammation, metabolic dysregulation, and gut microbiota imbalance. This study evaluated the safety and efficacy of a synbiotic formulation containing <i>Akkermansia muciniphila</i> Akk11 on gut microbiota composition, metabolic regulation, and obesity-associated inflammation.</p> Methods <p>A randomized, double-blind, placebo-controlled trial was conducted at Henan University of Technology. Adults aged 18–45 years with overweight or obesity (<i>n</i> = 110) were randomly assigned (1:1) to receive either a prebiotic placebo (control) or the synbiotic formulation containing <i>A. muciniphila</i> Akk11 (3.0 × 10<sup>10</sup> active fluorescent units [AFU] daily). Over 8 weeks, gut-microbiota composition was profiled by 16&#xa0;S ribosomal RNA gene sequencing, and serum biomarkers were quantified by enzyme-linked immunosorbent assay. Emotional well-being, sleep quality, and anthropometric measures were also assessed.</p> Results <p>After the 8-week intervention, the Akk11 group showed significant reductions in tumor necrosis factor-α, interleukin-6, and C-reactive protein and a significant increase in interleukin-25 versus baseline (all <i>p &lt;</i> 0.001). Relative to placebo, circulating Glucagon-Like Peptide-1 and Peptide YY (PYY) concentrations were higher (<i>p &lt;</i> 0.05), and Malondialdehyde levels were lower (<i>p &lt;</i> 0.01). Akk11 reduced the enrichment of <i>Escherichia coli</i>/<i>Shigella</i> and promoted the enrichment of beneficial genera, indicating a more favorable gut-microbiota structure. Waist-to-hip ratio decreased significantly (<i>p &lt;</i> 0.05), and significant reductions were observed in both Patient Health Questionnaire-9 and Pittsburgh Sleep Quality Index scores. No significant changes were detected in routine hematology, clinical chemistry, or blood glucose following Akk11 treatment.</p> Conclusion <p>The synbiotic formulation containing <i>A. muciniphila</i> Akk11 was well tolerated and may serve as a safe adjunctive strategy targeting microbiota-immune-metabolic interactions to alleviate obesity-associated metabolic and inflammatory disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of a synbiotic formulation containing Akkermansia muciniphila Akk11 on gut microbiota and metabolic health: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Chengsheng Zhu,
  • Yinhua Liu,
  • Zhiying Wang,
  • Ya Gao,
  • Fei Xu,
  • Jingyan Wang

摘要

Aim

Overweight and obesity are global public health challenges characterized by chronic low-grade inflammation, metabolic dysregulation, and gut microbiota imbalance. This study evaluated the safety and efficacy of a synbiotic formulation containing Akkermansia muciniphila Akk11 on gut microbiota composition, metabolic regulation, and obesity-associated inflammation.

Methods

A randomized, double-blind, placebo-controlled trial was conducted at Henan University of Technology. Adults aged 18–45 years with overweight or obesity (n = 110) were randomly assigned (1:1) to receive either a prebiotic placebo (control) or the synbiotic formulation containing A. muciniphila Akk11 (3.0 × 1010 active fluorescent units [AFU] daily). Over 8 weeks, gut-microbiota composition was profiled by 16 S ribosomal RNA gene sequencing, and serum biomarkers were quantified by enzyme-linked immunosorbent assay. Emotional well-being, sleep quality, and anthropometric measures were also assessed.

Results

After the 8-week intervention, the Akk11 group showed significant reductions in tumor necrosis factor-α, interleukin-6, and C-reactive protein and a significant increase in interleukin-25 versus baseline (all p < 0.001). Relative to placebo, circulating Glucagon-Like Peptide-1 and Peptide YY (PYY) concentrations were higher (p < 0.05), and Malondialdehyde levels were lower (p < 0.01). Akk11 reduced the enrichment of Escherichia coli/Shigella and promoted the enrichment of beneficial genera, indicating a more favorable gut-microbiota structure. Waist-to-hip ratio decreased significantly (p < 0.05), and significant reductions were observed in both Patient Health Questionnaire-9 and Pittsburgh Sleep Quality Index scores. No significant changes were detected in routine hematology, clinical chemistry, or blood glucose following Akk11 treatment.

Conclusion

The synbiotic formulation containing A. muciniphila Akk11 was well tolerated and may serve as a safe adjunctive strategy targeting microbiota-immune-metabolic interactions to alleviate obesity-associated metabolic and inflammatory disorders.